Prognostic factors and treatment outcomes of patients with uterine sarcoma: Analysis of 127 patients at a single institution, 1989-2007

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 12, 2008, Pages 1277-1287

  Park, Jeong Yeol ^a   Kim, Dae Yeon ^a   Suh, Dae Shik ^a   Kim, Jong Hyeok ^a   Kim, Yong Man ^a   Kim, Young Tak ^a   Nam, Joo Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Endometrial stromal sarcoma; Leiomyosarcoma; Malignant mixed mullerian tumor; Prognostic factor; Treatment outcome; Uterine sarcoma

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; PACLITAXEL; PLATINUM; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; ENDOMETRIUM SARCOMA; FEMALE; FOLLOW UP; HUMAN; LEIOMYOSARCOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MIXED TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UTERUS SARCOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOSARCOMA; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA, ENDOMETRIAL STROMAL; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 54949157193     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0422-2     Document Type: Article

References (37)

1. L Benoit L Arnould N Cheynel S Goui F Collin J Fraisse 2005 The role of surgery and treatment trends in uterine sarcoma Eur J Surg Oncol 31 434 442 10.1016/j.ejso.2005.01.010
2. SE Brooks M Zhan T Cote CR Baquet 2004 Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999 Gynecol Oncol 93 204 208 10.1016/j.ygyno.2003.12.029
3. L Chauveinc E Deniaud C Plancher X Sastre F Amsani A de la Rochefordiere 1999 Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments Gynecol Oncol 72 232 237 10.1006/gyno.1998.5251
4. R Coquard P Romestaing JM Ardiet F Mornex I Sentenac JP Gerard 1997 Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy Bull Cancer 84 625 629
5. DR Cox 1972 Regression models and life tables R Stat Soc B 34 187 220
6. D Denschlag I Masoud G Stanimir L Gilbert 2007 Prognostic factors and outcome in women with uterine sarcoma Eur J Surg Oncol 33 91 95 10.1016/j.ejso.2006.11.012
7. KE Dusenbery RA Potish PA Argenta PL Judson 2005 On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus Am J Clin Oncol 28 295 300 10.1097/01.coc. 0000156919.04133.98
8. G El Husseiny N Al Bareedy WA Mourad G Mohamed M Shoukri J Subhi 2002 Prognostic factors and treatment modalities in uterine sarcoma Am J Clin Oncol 25 256 260 10.1097/00000421-200206000-00010
9. A Gadducci A Romanini 2001 Adjuvant chemotherapy in early stage uterine sarcomas: an open question Eur J Gynaecol Oncol 22 352 357
10. A Gadducci E Sartori F Landoni P Zola T Maggino A Urgesi 1996 Endometrial stromal sarcoma: analysis of treatment failures and survival Gynecol Oncol 63 247 253 10.1006/gyno.1996.0314
11. A Gadducci S Cosio A Romanini AR Genazzani 2008 The management of patients with uterine sarcoma: A debated clinical challenge Crit Rev Oncol Hematol 65 129 142 10.1016/j.critrevonc.2007.06.011
12. M George MH Pejovic A Kramar 1986 Uterine sarcomas: prognostic factors and treatment modalities-study on 209 patients Gynecol Oncol 24 58 67 10.1016/0090-8258(86)90008-9
13. RL Giuntoli 2nd DS Metzinger CS DiMarco SS Cha JA Sloan GL Keeney 2003 Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy Gynecol Oncol 89 460 469 10.1016/S0090-8258(03)00137-9
14. E Gonzalez-Bosquet JM Martinez-Palones J Gonzalez-Bosquet A Garcia Jimenez J Xercavins 1997 Uterine sarcoma: a clinicopathological study of 93 cases Eur J Gynaecol Oncol 18 192 195
15. RE Hempling MS Piver TR Baker 1995 Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial Am J Clin Oncol 18 282 286 10.1097/00000421-199508000-00002
16. EL Kaplan P Meier 1958 Nonparametric extimator from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
17. KL Kelly PS Craighead 2005 Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Centre Int J Gynecol Cancer 15 132 139 10.1111/j.1048-891x.2005.15014.x
18. K Kokawa K Nishiyama M Ikeuchi Y Ihara N Akamatsu T Enomoto 2006 Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003) Int J Gynecol Cancer 16 1358 1363 10.1111/j.1525-1438.2006.00536.x
19. AJ Li RL Giuntoli 2nd R Drake SY Byun F Rojas D Barbuto 2005 Ovarian preservation in stage I low-grade endometrial stromal sarcomas Obstet Gynecol 106 1304 1308
20. L Livi E Andreopoulou N Shah F Paiar P Blake I Judson 2004 Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998 Clin Oncol (R Coll Radiol) 16 261 268 10.1016/j.clon.2004.01.010
21. FJ Major JA Blessing SG Silverberg CP Morrow WT Creasman JL Currie 1993 Prognostic factors in early-stage uterine sarcoma A Gynecologic Oncology Group study. Cancer 71 1702 1709
22. N Mantel 1966 Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 163 170
23. P Morice A Rodrigues P Pautier A Rey S Camatte D Atallah 2003 Surgery for uterine sarcoma: review of the literature and recommendations for the standard surgical procedure Gynecol Obstet Fertil 31 147 150 10.1016/S1297-9589(03)00061- 4
24. HB Muss B Bundy PJ DiSaia HD Homesley WC Fowler Jr W Creasman 1985 Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group) Cancer 55 1648 1653 10.1002/1097-0142(19850415)55: 8<1648::AID-CNCR2820550806>3.0.CO;2-7
25. RR Nordal SO Thoresen 1997 Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality Eur J Cancer 33 907 911 10.1016/S0959-8049(97) 00040-3
26. K Odunsi V Moneke J Tammela S Ghamande P Seago D Driscoll 2004 Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up Int J Gynecol Cancer 14 659 664 10.1111/j.1048-891X.2004. 14420.x
27. KS Olah H Gee S Blunt JA Dunn K Kelly KK Chan 1991 Retrospective analysis of 318 cases of uterine sarcoma Eur J Cancer 27 1095 1099
28. GA Omura JA Blessing F Major S Lifshitz CE Ehrlich C Mangan 1985 A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study J Clin Oncol 3 1240 1245
29. WA Peters 3rd NB Kumar WP Fleming GW Morley 1984 Prognostic features of sarcomas and mixed tumors of the endometrium Obstet Gynecol 63 550 556
30. N Reed C Mangioni H Malmstrom G Scarfone A Poveda S Tateo 2003 First results of a randomised trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. An EORTC-GCG study Int J Gynecol Cancer 13 4
31. A Rovirosa C Ascaso J Ordi R Abellana M Arenas JA Lejarcegui 2002 Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages Int J Radiat Oncol Biol Phys 52 1320 1329 10.1016/S0360-3016(01)02808-5
32. S Sagae K Yamashita S Ishioka Y Nishioka K Terasawa M Mori 2004 Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan Oncology 67 33 39 10.1159/000080283
33. AG Shumsky GC Stuart PM Brasher JG Nation DI Robertson S Sangkarat 1994 An evaluation of routine follow-up of patients treated for endometrial carcinoma Gynecol Oncol 55 229 233 10.1006/gyno.1994.1282
34. G Sutton VL Brunetto L Kilgore JT Soper R McGehee G Olt 2000 A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study Gynecol Oncol 79 147 153 10.1006/gyno.2000. 6001
35. G Sutton J Kauderer LF Carson SS Lentz CW Whitney H Gallion 2005 Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 96 630 634 10.1016/j.ygyno.2004.11.022
36. AH Wolfson DJ Wolfson SY Sittler L Breton AM Markoe JG Schwade 1994 A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas Gynecol Oncol 52 56 62 10.1006/gyno.1994.1011
37. TI Wu TC Chang S Hsueh KH Hsu HH Chou HJ Huang 2006 Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma Gynecol Oncol 100 166 172 10.1016/j.ygyno.2005.08.010